• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Intellia Therapeutics Inc.

    7/18/24 4:03:06 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NTLA alert in real time by email
    S-8 1 d873156ds8.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on July 18, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Intellia Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-37766   36-4785571
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)
    40 Erie Street, Suite 130  
    Cambridge, Massachusetts     02139
    (Address of Principal Executive Offices)     (Zip Code)

    Intellia Therapeutics, Inc. 2024 Inducement Plan

    (Full title of the plan)

    John Leonard, M.D.

    President and Chief Executive Officer

    40 Erie Street, Suite 130

    Cambridge, Massachusetts 02139

    (857) 285-6200

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Michael H. Bison, Esq.

    Gabriela Morales-Rivera, Esq.

    Goodwin Procter LLP

    100 Northern Ave.

    Boston, Massachusetts 02210

    (617) 570-1000

     

    James Basta, Esq.

    Executive Vice President, General Counsel

    Intellia Therapeutics, Inc.

    40 Erie Street, Suite 130

    Cambridge, Massachusetts 02139

    (857) 285-6200

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 registers 850,000 shares of Common Stock under the Intellia Therapeutics, Inc. 2024 Inducement Plan (the “Inducement Plan”).

    On June 21, 2024, the board of directors of Intellia Therapeutics, Inc. (the “Registrant”) adopted the Inducement Plan pursuant to which the Registrant reserved 850,000 shares of Common Stock to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Registrant, as an inducement material to the individual’s entry into employment with the Registrant within the meaning of Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market. The Inducement Plan provides for the grant of equity-based awards in the form of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, unrestricted stock awards, and dividend equivalent rights. The Inducement Plan was adopted by the Registrant’s board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market.


    Part I

    Information Required in the Section 10(a) Prospectus

    The documents containing the information specified in this Part I will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and the instructions to Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.

    Part II

    Information Required in the Registration Statement

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents filed with the SEC:

     

      (a)

    Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 22, 2024;

     

      (b)

    the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December  31, 2023 from its definitive proxy statement on Schedule 14A, filed with the SEC on April 29, 2024;

     

      (c)

    the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the SEC on May 9, 2024;

     

      (d)

    the Registrant’s Current Reports on Form 8-K filed with the SEC on January 4, 2024, February 23, 2024, March 22, 2024, April 15, 2024, June 13, 2024, June 14, 2024 and June 26, 2024; and

     

      (e)

    the description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-37766), filed by the Registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on May 5, 2016, including any amendments or reports filed for the purpose of updating such description.

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.


    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law permits a corporation to include in its charter documents, and in agreements between the corporation and its directors and officers, provisions expanding the scope of indemnification beyond that specifically provided by the current law.

    The Registrant’s second amended and restated certificate of incorporation, as amended, provides for the indemnification of directors and officers to the fullest extent permissible under Delaware law.

    The Registrant’s second amended and restated by-laws provide for the indemnification of officers, directors and third parties acting on the Registrant’s behalf if such persons act in good faith and in a manner reasonably believed to be in and not opposed to the Registrant’s best interest, and, with respect to any criminal action or proceeding, such indemnified party had no reason to believe his or her conduct was unlawful.

    The Registrant has entered into indemnification agreements with each of its directors and executive officers, in addition to the indemnification provisions provided for in its charter documents, and the Registrant intends to enter into indemnification agreements with any new directors and executive officers in the future. These agreements provide for indemnification for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were agents of the Registrant.

    The Registrant has purchased and maintains insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in that capacity, subject to certain exclusions and limits of the amount of coverage.

    These indemnification provisions and the indemnification agreements entered into between the Registrant and its officers and directors may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed in the Exhibit Index below and incorporated herein by reference.

    Item 9. Undertakings.

    (a) The Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act.

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement.

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.


    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    EXHIBIT INDEX

     

    Number

      

    Description

     4.1    Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K (File No. 001-37766) filed with the Securities and Exchange Commission on May 17, 2016)
     4.2    Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s AnnualReport on Form 10-K (File No. 001-37766) filed with the Securities and Exchange Commission on February 22, 2024)
     4.3    Second Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant dated June 12, 2024 (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-37766) filed with the Securities and Exchange Commission on June 13, 2024)
     4.4    Second Amended and Restated By-Laws of the Registrant (incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37766) filed with the Securities and Exchange Commission on May 7, 2020)
     5.1*    Opinion of Goodwin Procter LLP
    23.1*    Consent of Goodwin Procter LLP (included in Exhibit 5.1)
    23.2*    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
    24.1*    Power of attorney (included on the signature pages of this Registration Statement)
    99.1    Intellia Therapeutics, Inc. 2024 Inducement Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K (File No. 001-37766) filed with the Securities and Exchange Commission on June 26, 2024)
    107*    Filing Fee Table.

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 18th day of July, 2024.

     

    INTELLIA THERAPEUTICS, INC.
    By:  

    /s/ John Leonard

      John Leonard, M.D.
      President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of John Leonard, M.D. and James Basta, J.D. as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    Name   Title   Date

    /s/ John Leonard

      President, Chief Executive Officer and Director   July 18, 2024
    John Leonard, M.D.   (Principal Executive Officer)  

    /s/ Michael P. Dube

      Vice President, Chief Accounting Officer   July 18, 2024
    Michael P. Dube   (Principal Accounting Officer & Interim Principal Financial Officer)  

    /s/ Muna Bhanji

      Director   July 18, 2024
    Muna Bhanji, R.Ph.    

    /s/ Fred Cohen

      Director   July 18, 2024
    Fred Cohen, M.D., D.Phil.    

    /s/ Bill Chase

      Director   July 18, 2024
    Bill Chase    


    /s/ Brian Goff

      Director   July 18, 2024
    Brian Goff    

    /s/ Jesse Goodman

      Director   July 18, 2024
    Jesse Goodman, M.D.    

    /s/ Georgia Keresty

      Director   July 18, 2024
    Georgia Keresty, Ph.D.    

    /s/ Frank Verwiel

      Director   July 18, 2024
    Frank Verwiel, M.D.    
    Get the next $NTLA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTLA

    DatePrice TargetRatingAnalyst
    11/12/2025Outperform → Peer Perform
    Wolfe Research
    11/11/2025$8.00Outperform → In-line
    Evercore ISI
    11/7/2025$5.00Neutral → Underweight
    Analyst
    10/28/2025$14.00Outperform → Sector Perform
    RBC Capital Mkts
    10/28/2025Outperform → Mkt Perform
    Bernstein
    10/27/2025Outperform → Mkt Perform
    William Blair
    10/27/2025Buy → Neutral
    Guggenheim
    10/6/2025$33.00Mkt Perform → Mkt Outperform
    Citizens JMP
    More analyst ratings

    $NTLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Fred E bought $1,402,500 worth of shares (150,000 units at $9.35), increasing direct ownership by 261% to 207,453 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    1/7/26 4:05:06 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    8/22/25 4:30:14 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 30,600 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, In

    2/6/26 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine

    DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic diseases, enhancing crops, and engineering super-strong fibers. CRISPR ("Clustered Regularly Interspaced Short Palindromic Repeats") has gone from a niche academic breakthrough to one of the most transformative technologies of the 21st century. What started as a bacterial defense mechanism has become a programmable toolkit for rewriting genomes with unprecedented precision. Since its Nobel-winning discovery, CRISPR-based technologies have enabled targeted DNA modifications, opening doors to

    1/28/26 8:05:00 AM ET
    $CRSP
    $EDIT
    $NTLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

    Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). "We appreciate the FDA's expedit

    1/27/26 8:00:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Intellia Therapeutics Inc.

    SCHEDULE 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    2/12/26 2:39:36 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Intellia Therapeutics Inc.

    SCHEDULE 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    2/11/26 1:18:54 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SCHEDULE 13G filed by Intellia Therapeutics Inc.

    SCHEDULE 13G - Intellia Therapeutics, Inc. (0001652130) (Subject)

    2/9/26 6:42:03 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intellia Therapeutics downgraded by Wolfe Research

    Wolfe Research downgraded Intellia Therapeutics from Outperform to Peer Perform

    11/12/25 8:54:37 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Intellia Therapeutics from Outperform to In-line and set a new price target of $8.00

    11/11/25 8:02:05 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics downgraded by Analyst with a new price target

    Analyst downgraded Intellia Therapeutics from Neutral to Underweight and set a new price target of $5.00

    11/7/25 8:28:27 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Leonard John M sold $314,485 worth of shares (34,146 units at $9.21), decreasing direct ownership by 3% to 1,013,339 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    1/7/26 4:05:54 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    EVP, Chief Scientific Officer Schultes Birgit C sold $78,359 worth of shares (8,508 units at $9.21), decreasing direct ownership by 8% to 98,533 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    1/7/26 4:05:16 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Cohen Fred E bought $1,402,500 worth of shares (150,000 units at $9.35), increasing direct ownership by 261% to 207,453 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    1/7/26 4:05:06 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Leadership Updates

    Live Leadership Updates

    View All

    Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

    Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

    11/16/24 10:16:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

    Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do

    10/24/24 8:01:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

    - Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A

    10/10/24 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    2/13/24 5:07:59 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    1/29/24 4:00:59 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    1/24/24 11:21:06 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Financials

    Live finance-specific insights

    View All

    Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

    Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term Phase 1 clinical data for nex-z for ATTRv-PN in New England Journal of MedicineCompleted enrollment in Phase 3 HAELO clinical trial of lonvo-z for HAE; topline data expected by mid-2026 with potential U.S. commercial launch in 1H27Presenting longer-term Phase 1/2 clinical data of lonvo-z on November 8 at ACAAI 2025Ended third quarter with approximately $670 million in cash, cash equivalents and marketable securities; expected to fund operations into mid-2027 Conference call today a

    11/6/25 4:00:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

    CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively. This action follows a report on October 24, 2025 of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial on September 30, 2025, meeting the trial's protoco

    10/27/25 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

    Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections; Tracking to enroll at least 650 patients cumulatively by year-endExpanding total enrollment of the MAGNITUDE study to approximately 1,200 patients, subject to health authority review, with no expected impact on previous projected enrollment or financial runwayExpect to complete enrollment by first half 2026 in the global Phase 3 MAGNITUDE-2 study evaluating nex-z in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Expect to complete randomization in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) in heredita

    8/7/25 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care